Please login to the form below

Not currently logged in
Email:
Password:

monoclonal antibody drugs

This page shows the latest monoclonal antibody drugs news and features for those working in and with pharma, biotech and healthcare.

Novartis plans major expansion of French antibody facility

Novartis plans major expansion of French antibody facility

Novartis has set aside $100m to expand a production facility for monoclonal antibody (Mab) drugs in France, planning to boost capacity by 70%. ... inflammatory and anti-rejection drugs, as well as antibodies in late-stage clinical development.

Latest news

  • J&J starts to feel biosimilar competition bite J&J starts to feel biosimilar competition bite

    drugs. Revenues fell nearly 9% to $17.8bn, with prescription pharma sales fairly flat at $7.9bn as competition from Gilead Sciences and AbbVie's new hepatitis C virus therapies took ... towards the end of 2013 that the first monoclonal antibody (mAb)

  • EMA seeks comment on final biosimilar guidance EMA seeks comment on final biosimilar guidance

    cost versions of pricey branded medicines that account for a major chunk of the drugs budget in increasingly cash-strapped national healthcare systems. ... Growth will accelerate in the ensuing years, it says, as more and more copies of early-generation

  • Takeda files IBD drug vedolizumab in Europe Takeda files IBD drug vedolizumab in Europe

    Vedolizumab is a gut-selective monoclonal antibody that targets the alpha4beta7 integrin on leukocytes thought to be involved in the development of ulcerative colitis (UC) and Crohn's disease (CD), and ... UC - will outpace a decline in sales of older

  • India unveils biosimilar guidelines

    growth as the first-generation monoclonal antibody drugs lose patent protection. ... develop a portfolio of biosimilar medicines, focusing mainly on monoclonal antibodies used to treat cancer.

  • Biomarkers predict rheumatoid drug success

    had previously experienced an inadequate response to other disease-modifying anti-rheumatic drugs (DMARDs) were treated with the monoclonal antibody rituximab plus MTX. ... Additionally this will reduce treatment costs by avoiding the use of ineffective

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    In its late-stage pipeline Eisai has enviable prospects in oncology in the form of two very strong, innovative drugs. ... The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics